Cannabis Wheaton Income (TSXV:CBW) announced the launch of “Wheaton Licensing,” an accelerator platform to support entrepreneurs on all the stages of an application process to gain a licensed producer (LP) status in Canada.
As quoted in the press release:

Hugo Alves, President of Cannabis Wheaton, stated, “One of the great things about the experience the Cannabis Wheaton team has had to date is helping entrepreneurs succeed. Since joining Cannabis Wheaton, we have received a constant inbound flow of incredible entrepreneurs that we want to support and work with but are too early in the life cycle of their businesses to fit into our current streaming model. Establishing Wheaton Licensing is a way for us to help these entrepreneurs succeed in achieving their goals while facilitating our participation in these great opportunities. The goal is to cultivate these companies to be investment-ready and form the next cohort of Cannabis Wheaton streaming partners. In a way, Wheaton Licensing is the future of Cannabis Wheaton.”
Wheaton Licensing will allow a small group of entrepreneurial management teams to leverage the collective wisdom, knowledge, expertise and network of the Cannabis Wheaton team who have collectively worked on over 100 applications at each stage of the licensing process — from initial submission through to full sales license.


Click here to read the full press release.

Source: www.marketwired.com

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less